» Articles » PMID: 38568289

Ent-8(14),15-Pimaradiene-2β,19-diol, a Diterpene from Aleuritopteris Albofusca, Inhibits Growth and Induces Protective Autophagy in Hepatocellular Carcinoma Cells

Overview
Specialty Pharmacology
Date 2024 Apr 3
PMID 38568289
Authors
Affiliations
Soon will be listed here.
Abstract

A new pimarane-type diterpene, ent-8(14),15-pimaradiene-2β,19-diol (JXE-23), was isolated from the fern plant Aleuritopteris albofusca by our previous work; however, the biological activity of this diterpene remains unclear. In the present study, the anti-cancer potential of JXE-23 in various cancer cells was investigated. Among MCF-7 breast cancer cells, A549 lung cancer cells, and HepG2 liver cancer cells, JXE-23 displayed significant cytotoxicity to HepG2 cells with an IC value of 17.20 ± 1.73 µM, while showing no obvious toxicity in normal hepatocytes HL7702. JXE-23 inhibited cell growth and colony formation in HepG2 cells. A cell cycle distribution analysis showed that JXE-23 caused G2/M cell cycle arrest. Besides, JXE-23 also suppressed the migration of HepG2 cells. Interestingly, an increase of light chain 3 II (LC3II) and Beclin 1 and a decrease of P62 have occurred in JXE-23-treated cells, as well as the formation of GFP-LC3 dots, indicative of autophagy induction by JXE-23. When combined with autophagy inhibitor 3-methyladenine and chloroquine, the cell viability was significantly reduced, suggesting that JXE-23 triggered protective autophagy in hepatoma cells. Further study showed that JXE-23 inactivated the CIP2A/p-AKT/c-Myc signaling axis in HepG2 cells. Our data provided evidence that JXE-23 inhibited cell growth, arrested cells at the G2/M phase, and induced protective autophagy in HepG2 hepatocellular carcinoma cells. JXE-23 may be a potential lead compound for anti-cancer drug development, and autophagy inhibitor treatment may provide an effective strategy for improving its anti-cancer effect.

Citing Articles

Targeting cell death mechanisms: the potential of autophagy and ferroptosis in hepatocellular carcinoma therapy.

Liu B, Liu L, Liu Y Front Immunol. 2024; 15:1450487.

PMID: 39315094 PMC: 11416969. DOI: 10.3389/fimmu.2024.1450487.

References
1.
Aiello N, Maddipati R, Norgard R, Balli D, Li J, Yuan S . EMT Subtype Influences Epithelial Plasticity and Mode of Cell Migration. Dev Cell. 2018; 45(6):681-695.e4. PMC: 6014628. DOI: 10.1016/j.devcel.2018.05.027. View

2.
Booth L, Roberts J, Poklepovic A, Dent P . Autophagy as a therapeutic mechanism to kill drug-resistant cancer cells. Anticancer Drugs. 2023; 35(2):177-182. DOI: 10.1097/CAD.0000000000001549. View

3.
Cao H, Chai T, Wang X, Morais-Braga M, Yang J, Wong F . Phytochemicals from fern species: potential for medicine applications. Phytochem Rev. 2020; 16(3):379-440. PMC: 7089528. DOI: 10.1007/s11101-016-9488-7. View

4.
Chakraborty E, Sarkar D . Emerging Therapies for Hepatocellular Carcinoma (HCC). Cancers (Basel). 2022; 14(11). PMC: 9179883. DOI: 10.3390/cancers14112798. View

5.
Chen Y, Azad M, Gibson S . Methods for detecting autophagy and determining autophagy-induced cell death. Can J Physiol Pharmacol. 2010; 88(3):285-95. DOI: 10.1139/Y10-010. View